Burkitt Lymphoma | VJHemOnc

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

View Aggressive & Diffuse Large B-Cell Lymphoma Overview Page

An analysis of the risk factors associated with disease progression in patients with BL

An analysis of the risk factors associated with disease progression in patients with BL

Mark Roschewski • 14 Dec 2021

Treating lymphoma in the developing world

Treating lymphoma in the developing world

Franco Cavalli • 24 Jun 2021

Diagnosing and treating NHL in teenagers and young adults

Diagnosing and treating NHL in teenagers and young adults

Robert Carr • 22 Jun 2021

Developing the novel Burkitt Lymphoma International Prognostic Index

Developing the novel Burkitt Lymphoma International Prognostic Index

Adam Olszewski • 8 Dec 2020

CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool

CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool

Adam Olszewski • 8 Dec 2020

IVAC +/- rituximab in R/R B-NHLs: a real-world data review

IVAC +/- rituximab in R/R B-NHLs: a real-world data review

David J. Straus • 2 Dec 2020

New technologies informing SOC in DLBCL

New technologies informing SOC in DLBCL

Christian Gisselbrecht • 14 Jun 2018

Describing clonal evolution in lymphoma

Describing clonal evolution in lymphoma

Michael Pfreundschuh et al. • 8 Sep 2017

Acute leukemia: epidemiology and progress in treatment

Acute leukemia: epidemiology and progress in treatment

Elias Jabbour • 4 Dec 2015

Panel discussion on the treatment of adolescent and young adult lymphoma patients

Panel discussion on the treatment of adolescent and young adult lymphoma patients

Catherine Bollard et al. • 23 Sep 2016